Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE)
Health Care · Biotechnology · US
$10.30
-0.19% today · +21.7% 1Y
Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $878.73M and employs 173 people.
Over the last twelve months the share price has gained 21.7%, trading between 7.24 and 25.77.
Tweenvest scores Monte Rosa Therapeutics, Inc. across four factors: quality 53/100, value 63/100. Its strongest factor is value.
GLUE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $878.73M
- Revenue (TTM)
- $28.73M
- P/E
- —
- EPS
- -1.74
- Dividend yield
- —
- Beta (5Y)
- 1.37
- 52-week high
- $25.77
- 52-week low
- $7.24
- Avg volume (3M)
- —
- Shares outstanding
- 85.31M
- Employees
- 173
- Next earnings
- —
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
- ISIN
- US61225M1027
- Founded
- 2019
- Listed since
- Jun 24, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Alphamab OncologySEHK: 9966 | $907.71M | HK$7.36 | -11.44% |
| Frontier Biotechnologies Inc.SHSE: 688221 | $886.38M | CN¥15.85 | -6.05% |
| Corvus Pharmaceuticals, Inc.NasdaqGM: CRVS | $884.95M | $10.52 | -3.49% |
| Beijing SL Pharmaceutical Co., Ltd.SZSE: 002038 | $883.46M | CN¥5.76 | +0.17% |
| Lepu Biopharma Co., Ltd.SEHK: 2157 | $878.35M | HK$3.82 | -5.56% |
| Kuros Biosciences AGSWX: KURN | $878.10M | CHF18.35 | -1.50% |
| PeptiDream Inc.TSE: 4587 | $872.86M | ¥1,075.00 | +2.14% |
| Hangzhou Biotest Biotech Co.,Ltd.SHSE: 688767 | $865.08M | CN¥39.60 | -1.49% |
Figures last refreshed Oct 11, 2026.